Drug Utilization Study for azilsartan medoxomil in Germany

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/28627
• EU PAS number:
  EUPAS7998
• Study ID:
  28627
• Official title and acronym:
  Drug Utilization Study for azilsartan medoxomil in Germany
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  A retrospective analyses of the IMS Disease Analyzer database to describe prescribing and morbidity patterns in patients prescribed azilsartan medoxomil in Germany.
• Study status:
  Finalised

Research institution and networks

Institutions

Real World Evidence Solutions, IMS Health

France

Study timelines

Date when funding contract was signed

Planned: 31/03/2014

Actual: 31/10/2014

Study start date

Planned: 30/06/2014

Actual: 01/11/2014

Data analysis start date

Planned: 30/06/2014

Actual: 01/11/2014

Date of interim report, if expected

Planned: 31/12/2014

Actual: 01/10/2017

Date of final study report

Planned: 31/12/2018

Actual: 29/10/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

TDC Europe

Study protocol

Initial protocol

Azilsmedox-5007 study protocol Drug Utilization Study IMS Germany_Version_13022014 13 May 2014

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable